Chronic in utero oxycodone exposure alters placental small EV proteome and fetal cardiomyopathy-linked pathways

Abstract

Aim: The rising prevalence of opioid use during pregnancy poses serious public health concerns. The placenta is a critical organ during gestation, and opioid exposure can disrupt its function and fetal development. However, the molecular mechanisms through which opioids such as oxycodone affect feto-placental development remain poorly understood. This study aimed to investigate the effects of chronic in-utero oxycodone exposure on the composition and signaling functions of placenta-derived small extracellular vesicles (PSEVs) using a rat model.

Methods: Extracellular vesicles (EVs) were isolated from placental tissue and characterized through nanoparticle tracking analysis, transmission electron microscopy, western blotting, and label-free quantitative proteomics. Bioinformatic enrichment analyses were conducted to evaluate changes in EVs biophysical properties and protein cargo.

Results: Chronic oxycodone exposure significantly altered PSEV characteristics, including particle size distribution and proteomic composition. Among the 456 identified EV proteins, 107 proteins were significantly dysregulated. We found key downregulatory proteins including Atp2a2, Lmna, Tgfb3, Agt, and Sgce, which are crucial for myocardial calcium cycling, nuclear integrity, extracellular matrix remodeling, and blood pressure regulation. These findings indicate disruptions in fetal cardiac programming, particularly hypertrophic and dilated cardiomyopathy pathways. Additionally, enrichment analyses revealed notable perturbations in metabolic processes (e.g., citrate cycle, fatty acid degradation, N-glycan biosynthesis), along with upregulation of vesicle transport and neurodevelopment-related proteins, indicating broader systemic effects on fetal development. While these proteomic findings are robust, further independent validation (e.g., via targeted assays or Western blotting) will be necessary to confirm individual protein-level changes.

Conclusion: These results highlight PSEVs as sensitive molecular indicators linking maternal oxycodone use to disrupted fetal cardiovascular, metabolic, and neurodevelopmental pathways. This study provides a novel systems-level framework for understanding opioid-induced placental signaling alterations and lays the groundwork for developing EV-based diagnostic biomarkers and targeted interventions.

Keywords

Oxycodone / EVs / proteomics / cardiomyopathy / fetal development / EV biomarkers / perinatal exposure / placental signaling

References

[1] Moradi M,Shoar S.Use of oxycodone in pain management.Anesth Pain Med2012;1:262-4 PMCID:PMC4018705

[2] Kibaly C,Liu SH.Oxycodone in the opioid epidemic: high ‘liking’, ‘wanting’, and abuse liability.Cell Mol Neurobiol2021;41:899-926 PMCID:PMC8155122

[3] Giovannini E,Pascali JP.Fetal and infant effects of maternal opioid use during pregnancy: a literature review including clinical, toxicological, pharmacogenomic, and epigenetic aspects for forensic evaluation.Children2024;11:278 PMCID:PMC10969201

[4] Radhakrishna U,Uppala LV.Prenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome.Front Pain Res2025;6:1497801 PMCID:PMC12043715

[5] Yen E.The immediate and long-term effects of prenatal opioid exposure.Front Pediatr2022;10:1039055 PMCID:PMC9676971

[6] Feng Y,Chen Q.Normotensive placental extracellular vesicles provide long-term protection against hypertension and cardiovascular disease.Am J Obstet Gynecol2024;231:350.e1-24

[7] Darbinian N,Tatevosian G.Prenatal opioid and alcohol exposures: association with altered placental serotonin transporter structure and/or expression.Int J Mol Sci2024;25:11570 PMCID:PMC11546934

[8] Jeyarajah MJ,Jaju Bhattad G,Whitehead SN.Placental extracellular vesicles promote cardiomyocyte maturation and fetal heart development.Commun Biol2024;7:1254 PMCID:PMC11450004

[9] Broussard CS, Rasmussen SA, Reefhuis J, et al.; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects.Am J Obstet Gynecol2011;204:314.e1-11

[10] Esposito DB,Werler M.Ischemic placental disease, preterm delivery, and their association with opioid use during pregnancy.Am J Epidemiol2022;191:759-68 PMCID:PMC9430412

[11] Green MT,Kinkade JA.Maternal oxycodone treatment causes pathophysiological changes in the mouse placenta.Placenta2020;100:96-110 PMCID:PMC8112023

[12] Ahmed N,Malone J.Prenatal morphine exposure increases cardiovascular disease risk and programs neurogenic hypertension in the adult offspring.Hypertension2023;80:1283-96 PMCID:PMC10274123

[13] Odegaard KE,Clark AR.A holistic systems approach to characterize the impact of pre- and post-natal oxycodone exposure on neurodevelopment and behavior.Front Cell Dev Biol2020;8:619199 PMCID:PMC7817773

[14] Goetzl L,Darbinian N.Novel biomarkers to assess in utero effects of maternal opioid use: first steps toward understanding short- and long-term neurodevelopmental sequelae.Genes Brain Behav2019;18:e12583 PMCID:PMC7074845

[15] Nguyen NM,Guda C.Decoding the synaptic proteome with long-term exposure to midazolam during early development.Int J Mol Sci2022;23:4137 PMCID:PMC9027542

[16] Odegaard KE,Clark AR.Characterization of the intergenerational impact of in utero and postnatal oxycodone exposure.Transl Psychiatry2020;10:329 PMCID:PMC7511347

[17] Lyu Z,Bivens NJ,Joshi T.Effects of oxycodone on placental lineages: Evidence from the transcriptome profile of mouse trophoblast giant cells.Proc Natl Acad Sci U S A2024;121:e2412349121 PMCID:PMC11551428

[18] Minakova E,Mikati MO.Ontogenetic oxycodone exposure affects early life communicative behaviors, sensorimotor reflexes, and weight trajectory in mice.Front Behav Neurosci2021;15:615798 PMCID:PMC7937712

[19] Flores A,Devanaboyina M.Neurobehavioral characterization of perinatal oxycodone-exposed offspring in early adolescence.J Neuroimmune Pharmacol2024;19:29

[20] Chand S,Savine M.A comprehensive study to delineate the role of an extracellular vesicle-associated microRNA-29a in chronic methamphetamine use disorder.J Extracell Vesicles2021;10:e12177 PMCID:PMC8674191

[21] Koul S,Chand S.Role of brain derived extracellular vesicles in decoding sex differences associated with nicotine self-administration.Cells2020;9:1883 PMCID:PMC7464419

[22] Nguyen NM,Meyer L.Identification of YWHAH as a novel brain-derived extracellular vesicle marker post long-term midazolam exposure during early development.Cells2023;12:966 PMCID:PMC10047367

[23] Shahjin F,Schaal VL.Brain-derived extracellular vesicle microRNA signatures associated with in utero and postnatal oxycodone exposure.Cells2019;9:21 PMCID:PMC7016745

[24] Kannan M,Chemparathy DT.HIV-1 Tat induced microglial EVs leads to neuronal synaptodendritic injury: microglia-neuron cross-talk in NeuroHIV.Extracell Vesicles Circ Nucl Acids2022;3:133-49 PMCID:PMC9937449

[25] Meyer D,Gowen A.Effect of combined methamphetamine and oxycodone use on the synaptic proteome in an in vitro model of polysubstance use.Genes2022;13:1816 PMCID:PMC9601452

[26] Nakahara A,Ormazabal V.Circulating placental extracellular vesicles and their potential roles during pregnancy.Ochsner J2020;20:439-45 PMCID:PMC7755551

[27] Sun Q,Wang H.Regulatory roles of extracellular vesicles in pregnancy complications.J Adv Res2025;78:363-75 PMCID:PMC12684912

[28] Dai H.MGST1 alleviates the oxidative stress of trophoblast cells induced by hypoxia/reoxygenation and promotes cell proliferation, migration, and invasion by activating the PI3K/AKT/mTOR pathway.Open Med2022;17:2062-71 PMCID:PMC9755705

[29] Reimers A,Stuen I.Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term.Eur J Drug Metab Pharmacokinet2011;35:79-82 PMCID:PMC3034912

[30] Collier AC,Tingle MD.UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.Biochem Pharmacol2002;63:409-19

[31] Kawase T,Shibata T.PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt.Cell2009;136:535-50

[32] Butelman ER,Nwaneshiudu CA.Neuroimmune mechanisms of opioid use disorder and recovery: translatability to human studies, and future research directions.Neuroscience2023;528:102-16 PMCID:PMC10720374

[33] Hansen SSK,Rago D.Pulmonary maternal immune activation does not cross the placenta but leads to fetal metabolic adaptation.Nat Commun2024;15:4711 PMCID:PMC11148039

[34] Giussani DA,Niu Y.Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress.PLoS One2012;7:e31017 PMCID:PMC3278440

[35] Aljunaidy MM,Cooke CM.Prenatal hypoxia and placental oxidative stress: linkages to developmental origins of cardiovascular disease.Am J Physiol Regul Integr Comp Physiol2017;313:R395-9

[36] Julian CG,Fallahi S.Altered placental ion channel gene expression in preeclamptic high-altitude pregnancies.Physiol Genomics2023;55:357-67 PMCID:PMC10642922

[37] Chen L,Wu Q.Maternal serum Lamin A is a potential biomarker that can predict adverse pregnancy outcomes.EBioMedicine2022;77:103932 PMCID:PMC8924630

[38] Rosenkranz S.TGF-beta1 and angiotensin networking in cardiac remodeling.Cardiovasc Res2004;63:423-32

[39] Santos MC,Pham T.Angiotensin II-induced cardiac fibrosis and dysfunction are exacerbated by deletion of cGKI in periostin+ myofibroblasts.Clin Sci2025;139:507-26 PMCID:PMC12247847

[40] Wang Y,Zhao M,Harrison C.Multiple soluble TGF-β receptors in addition to soluble endoglin are elevated in preeclamptic serum and they synergistically inhibit TGF-β signaling.J Clin Endocrinol Metab2017;102:3065-74 PMCID:PMC5546862

[41] Soncin F,To C.Comparative analysis of mouse and human placentae across gestation reveals species-specific regulators of placental development.Development2018;145:dev156273 PMCID:PMC5825847

[42] Schuster J,Padbury J.Placental extracellular vesicles and pre-eclampsia.Am J Reprod Immunol2021;85:e13297 PMCID:PMC7779690